Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings(University of Copenhagen), Michael Dickinson(The University of Melbourne), David Pérez-Callejo(Roche (Switzerland)), Maja Weisser(Roche Pharma AG (Germany)), Natalie Dimier(Roche (United Kingdom)), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Pablo Umaña(Zurich Insurance Group (Switzerland)), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Carmelo Carlo‐Stella(Humanitas University), Anton Belousov(Roche (Switzerland)), Franck Morschhauser(Hôpital Claude Huriez), Michael Crump(University of Toronto), Cristiano Ferlini(La Roche College), Tom Moore(Roche Pharma AG (Germany)), Ann-Marie E Bröske(Roche (Switzerland)), Linda Lundberg(Roche (Switzerland)), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), David Carlile(Roche (Switzerland)), Gilles Salles(Memorial Sloan Kettering Cancer Center), Denise Thomas(La Roche College), Marina Bacac(Roche (Switzerland)), Fritz Offner(Ghent University Hospital), Peter N. Morcos(Roche (United States))
Cited by 428
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k